ResearchMoz.us: ENT Disorders Market Forecast 2017 - Reach $17.2 billion, Indicating a CAGR of 1.6% PR Newswire ALBANY, New York, September 11, 2013 ALBANY, New York, September 11, 2013 /PRNewswire/ -- New Report Added in ResearchMoz Reports Database Global ENT Disorders Market Forecast 2017 - Reach $17.2 billion, Indicating a CAGR of 1.6% ResearchMoz announces that it has published a new study Global ENT Disorders Market Forecast 2017 - Reach $17.2 billion, Indicating a CAGR of 1.6% The leading business intelligence provider, has released its latest research, "ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance", which provides in-depth analysis of the unmet needs, drivers and barriers that affect the global ENT disorders therapeutics market. The report analyzes the markets for ENT disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales value and annual cost of therapy are forecast until 2017 for key geographies in the five leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers and acquisitions (M&A) and licensing agreements that shape the global markets. Browse Complete Report with TOC@ http://www.researchmoz.us/ent-disorders-market-to-2017--cephalosporins-quinolones-and-macrolides-to-replace-older-therapies-due-to-anti-bacterial-resistance-report.html The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. Analysis shows that the ENT disorders market will continue to grow marginally, largely due to the growing population and deteriorating environmental conditions. The prime reasons for the slow growth of the market are the generic domination and the weak product pipelines for all five key indications. The global ENT disorders market was estimated to be worth $15.3 billion in 2010, having grown at a compound annual growth rate (CAGR) of 0.7% between 2002 and 2010. By 2017, the global ENT disorders market is forecast to reach $17.2 billion, indicating a CAGR of 1.6% between 2010 and 2017.The ENT disorders M&A landscape has seen low levels of activity over the last decade, with only 16 deals signed from 2004-2011. The therapeutic area of focus for the M&A deals from 2004-2011 remained highly concentrated for sinusitis. Some deals had multiple ENT disorders as their therapeutic area of focus. Scope Annualized market data for the ENT disorders market from 2002 to 2010, forecast forward to 2017. Analysis of the leading therapeutic segments, including tonsillitis, sinusitis, rhinitis, otitis media and tracheobronchitis. Analysis of the ENT disorders market in the leading geographies globally, which include the US, the UK, Germany, France, Italy, Spain and Japan. Market characterization of the ENT disorders market, including market size, annual cost of therapy and treatment usage patterns Key drivers and barriers that have a significant impact on the market Coverage of pipeline molecules in the various phases of drug development Competitive benchmarking of leading companies. The key companies studied in this report are Abbott Laboratories, Bayer AG, Eli Lilly, GSK, J&J, Novartis AG, Merck & Co., Pfizer and Sanofi. Key M&A activities and licensing agreements that have taken place between 2004 and mid-2011 in the global ENT disorders market Find More Reports of Surgical Equipment Market @ http://www.researchmoz.us/surgical-equipment-market-reports-53.html Reasons to buy Align your product portfolio to the markets with high growth potential. Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth. Reinforce R&D pipelines by identifying new target mechanisms that can produce first-in-class molecules with more efficiency and better safety. Develop key strategic initiatives by understanding the key focus areas of leading companies. Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps. Popular Market Research Reports Report: US Nurse Call System Equipment Market 2012-2016: Analysts forecast the Nurse Call System Equipment market in the US to grow at a CAGR of 13.66 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing elderly population. The Nurse Call System Equipment market in the US has also been witnessing the integration of nurse call systems with wireless technologies. However, the lack of awareness of advanced technologies available could pose a challenge to the growth of this market.TechNavio's report, the Nurse Call System Equipment Market in the US 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Nurse Call System Equipment market in the US landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Browse Complete Report@ http://www.researchmoz.us/nurse-call-system-equipment-market-in-the-us-2012-2016-report.html Mobile Phone Indoor Positioning Systems (IPS) and Real Time Locating Systems (RTLS) 2013-2023: Indoor Positioning Systems (IPS) primarily concerns location-based services on mobile phones where GPS does not work. The term Real Time Locating Systems (RTLS) primarily concerns locating people and things at a distance, securely, using second generation RFID. The subjects are converging with Apple, Samsung, Google, Nokia, Microsoft, Hewlett Packard and IBM clashing for the tens of millions of dollars of business that is emerging. The first $0.5 billion order has been landed. This subject heavily involves short range communications notably WiFi and Bluetooth and inertial navigation and advanced RFID as it progresses to determining 3D position including orientation and line of travel. Emergency services, healthcare, retailing, manufacturing, logistics and many other industries will be transformed by what is becoming possible. The winners in making and operating mobile phones will offer the most compelling new functionality, IPS being a major enabler. The winners in making, integrating and operating RTLS will reduce cost and improve usefulness, not least to encompass mobile phones and other mobile computing. The world's largest companies are locking horns on this. The topics of IPS and RTLS embrace a value chain from research and consultancy to software, services, hardware, integration and facilities management. Mobile phone app developers and value added enhancements plus ecosystems of mobile phones, web services and more are also involved. Browse Complete Report@ http://www.researchmoz.us/mobile-phone-indoor-positioning-systems-ips-and-real-time-locating-systems-rtls-2013-2023-report.html ### Mobile Phone Insurance Revenue by Country & Region Database: 2013 - 2018 ( http://www.researchmoz.us/mobile-phone-insurance-revenue-by-country-and-region-database-2013-2018-report.html ) The mobile phone insurance industry is increasingly gaining momentum. As device vendors intensely compete by launching new and unique Smartphone models, insurance companies are heavily capitalizing on device specific insurance plans. With global revenues of over $30 Billion in 2013, the industry is set to grow at a CAGR of 17 % over the next five years. By 2018, it is estimated that the industry would be worth $61 Billion. The "Mobile Phone Insurance Revenue by Country & Region Database: 2013 - 2018" tracks historical revenues and yearly forecasts for the global mobile insurance industry at both country and regional levels. Browse Complete Report@ http://www.researchmoz.us/mobile-phone-insurance-revenue-by-country-and-region-database-2013-2018-report.html ### The Taiwanese Mobile Phone Industry, 3Q 2013: Branded Vendors: This research report presents mobile phone shipment volume forecast and recent quarter review of major Taiwanese branded vendors. The report includes shipment volume and value, ASP, vendor volume ranking, shipment by brands, and price trend. Also provided are shipment breakdowns by system technology, operating system, display technology, panel size, shipment destination, and production location. The content of this report is based on primary data obtained through interviews with Taiwanese mobile phone branded vendors. The report finds that the shipment volume of Taiwanese mobile phone branded vendors grew sequentially in the second quarter of 2013, mainly ascribed to resumed production capacity following the relief to the shortage of high-end components. Nevertheless, it is anticipated that without effective marketing strategies in place, Taiwanese branded mobile phone shipment volume will suffer from a double-digit decline in the second half of 2013 compared to the first. Browse Complete Report@ http://www.researchmoz.us/the-taiwanese-mobile-phone-industry-3q-2013-branded-vendors-report.html Table of Contents 1.1 List of Tables 1.2 List of Figures 2 ENT Disorders Market - Introduction 2.1 GBI Research Report Guidance 3 ENT Disorders Market - Market Overview 3.1 Rising Global Population and Deteriorating Environmental Conditions Drive ENT Disorder Therapeutics 3.2 Gross Maldistribution 3.3 ENT Disorders Marked By Antibiotic Overuse 3.4 Entry of New Players Restricted by the Number of Generics and Stringent FDA Regulations 3.4.1 Ketolides - A New Class of Antibacterials 3.5 Revenue Forecasts 3.6 Annual Cost of Therapy 3.7 Treatment Usage Patterns 3.7.1 Diseased Population 3.7.2 Treatment Seeking Population 3.7.3 Diagnosed Population 3.7.4 Prescription Population 3.8 Drivers and Restraints of the ENT Disorders Market 3.8.1 ENT Disorders Market Drivers 3.8.2 ENT Disorders Market Restraints 4 ENT Disorders Market - Therapeutic Landscape 4.1 Tonsillitis Market 4.1.1 Introduction 4.1.2 Revenue Forecasts 4.1.3 Annual Cost of Therapy 4.1.4 Treatment Flow Algorithm 4.1.5 Treatment Usage Patterns 4.1.6 Profiles of Key Drugs in the Tonsillitis Market 4.1.7 Geographical Segmentation 4.2 Sinusitis Market 4.2.1 Introduction 4.2.2 Revenue Forecasts 4.2.3 Annual Cost of Therapy 4.2.4 Treatment Flow Algorithm 4.2.5 Treatment Usage Patterns 4.2.6 Profiles of Key Drugs in the Sinusitis Market 4.2.7 Geographical Segmentation 4.3 Rhinitis Market 4.3.1 Introduction 4.3.2 Revenue Forecasts 4.3.3 Annual Cost of Therapy 4.3.4 Treatment Flow Algorithm 4.3.5 Treatment Usage Patterns 4.3.6 Profiles of Key Drugs in the Rhinitis Market 4.3.7 Geographical Segmentation 4.4 Otitis Media Market 4.4.1 Introduction 4.4.2 Revenue Forecasts 4.4.3 Annual Cost of Therapy 4.4.4 Treatment Flow Algorithm 4.4.5 Treatment Usage Patterns 4.4.6 Profiles of Key Drugs in the Otitis Media Market 4.4.7 Geographical Segmentation 4.5 Tracheobronchitis Market 4.5.1 Introduction 4.5.2 Revenue Forecasts 4.5.3 Annual Cost of Therapy 4.5.4 Treatment Flow Algorithm 4.5.5 Treatment Usage Patterns 4.5.6 Profiles of Key Drugs in the Tracheobronchitis Market 4.5.7 Geographical Segmentation 5 ENT Disorders Market - Geographical Landscape 5.1 The US 5.1.1 Revenue Forecasts 5.1.2 Annual Cost of Therapy 5.1.3 Treatment Usage Patterns 5.2 Top Five Countries in Europe 5.2.1 Revenue Forecasts 5.2.2 Annual Cost of Therapy 5.2.3 Treatment Usage Patterns 5.3 Japan 5.3.1 Revenue Forecasts 5.3.2 Annual Cost of Therapy 5.3.3 Treatment Usage Patterns 6 ENT Disorders Market - Pipeline Analysis 6.1 Introduction 6.1.1 Research and Development Pipeline - Tonsillitis 6.1.2 Research and Development Pipeline - Sinusitis 6.1.3 Research and Development Pipeline - Rhinitis 6.1.4 Research and Development Pipeline - Otitis Media 7 ENT Disorders Market - Competitive Landscape 7.1 Competitive Profiling 7.1.1 Abbott Laboratories 7.1.2 Bayer AG 7.1.3 GlaxoSmithKline 7.1.4 Johnson & Johnson (J&J) 7.1.5 Merck & Co 7.1.6 Pfizer 7.1.7 Novartis AG 7.1.8 F. Hoffmann-La Roche Ltd. 7.1.9 Sanofi 8 ENT Disorders Market - Strategic Consolidations 8.1 Overview 8.2 ENT Disorders Market M&A Deals 8.2.1 M&A Deals by Geography 8.2.2 Deals by Type 8.2.3 Major M&A Deals 8.3 R&D Licensing Agreements 8.3.1 Deals by Indication 8.3.2 Deals by Geography 8.3.3 MerLion Pharmaceuticals Enters Into Licensing Agreement with Alcon Pharmaceuticals for Finafloxacin 9 ENT Disorders Market - Appendix 9.1 Market Definitions 9.2 Abbreviations 9.3 Research Methodology 9.3.1 Coverage 9.3.2 Secondary Research 9.3.3 Primary Research 9.3.4 Geographical Landscape 9.3.5 Pipeline Analysis 9.3.6 Competitive Landscape 9.3.7 Expert Panel Validation 9.4 Contact Us 9.5 Disclaimer 9.6 Sources Browse Complete Report with TOC@ http://www.researchmoz.us/ent-disorders-market-to-2017--cephalosporins-quinolones-and-macrolides-to-replace-older-therapies-due-to-anti-bacterial-resistance-report.html About Us ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis . We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact M/s Sheela 90 Sate Street, Suite 700Albany, NY 12207 Tel: +1-518-618-1030USA - Canada Toll Free: 866-997-4948 Email: firstname.lastname@example.org http://www.researchmoz.us/ http://www.researchmoz.blogspot.com/
ResearchMoz.us: ENT Disorders Market Forecast 2017 - Reach $17.2 billion, Indicating a CAGR of 1.6%
Press spacebar to pause and continue. Press esc to stop.